Streetbeat News

Products Services

THAR

Tharimmune Inc (NASDAQ:THAR) reported positive Phase 1 data for TH104, a transmucosal buccal film, showing higher bioavailability and similar pharmacokinetics compared to a European tablet. The studies indicated potential benefits for patients with impaired liver function and consistent safety profiles. The company plans to discuss Phase 2 trial design with the FDA and expects topline data in 2024 for treating chronic pruritis in primary biliary cholangitis patients. THAR's stock price surged 50% to $4.32.

Portfolio Pulse from Vandana Singh

November 27, 2023 | 3:01 pm

USDCUSD

Circle, the issuer of the USDC stablecoin, has partnered with SBI Holdings to expand the use of USDC and Circle's Web3 services in Japan. The collaboration aims to ensure compliance with stablecoin regulations and seeks approvals for SBI VC Trade Co to operate as an electronic payment instruments service. SBI Shinsei Bank Ltd. will provide banking services to support stablecoin access and liquidity in Japan. The partnership aligns with Japan's revised Payment Services Act and SBI's digital asset strategy.

Portfolio Pulse from Khyathi Dalal

November 27, 2023 | 2:54 pm

AFRM

Affirm Holdings Inc.'s stock (AFRM) is trading higher due to reports predicting record usage of 'buy now, pay later' services during Cyber Monday.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 2:51 pm

AWH

Aspira Women's Health has received the final crosswalk pricing determination from the Centers for Medicare & Medicaid Services (CMS). CMS has set the 2024 price for Aspira's OvaWatchSM test at $897 per test.

Portfolio Pulse from Bill Haddad

November 27, 2023 | 2:48 pm

TCBP

TC Biopharm's stock price has risen following the announcement that the FDA has cleared the Phase 1B Investigational New Drug (IND) application for TCB-008, a treatment for Acute Myeloid Leukemia.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 2:47 pm

BDRX

BGLC

IMPL

PRQR

RDHL

SHOP

THAR

U.S. stocks opened lower on Monday, with the Dow Jones down by over 50 points. Shopify Inc (SHOP) reported a record $4.1 billion in Black Friday sales, a 22% increase from last year. RedHill Biopharma (RDHL), Biodexa Pharmaceuticals (BDRX), and Tharimmune (THAR) saw their stocks surge on positive news, while BioNexus Gene Lab (BGLC), Impel Pharmaceuticals (IMPL), and ProQR Therapeutics (PRQR) experienced declines. Oil prices dipped slightly, while gold and silver saw gains.

Portfolio Pulse from Lisa Levin

November 27, 2023 | 2:46 pm

THAR

Tharimmune shares have seen an increase in trading activity following the announcement of positive Phase 1 data for their drug TH104. This development could potentially lead to further clinical trials and advancements in the company's pipeline, attracting investor interest.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 2:46 pm

AFRM

Affirm Holdings Inc (NYSE:AFRM) stock is trading higher due to expectations of record Cyber Monday sales, with projections of $12 billion to $12.4 billion, surpassing initial estimates. The growth is partly attributed to the 'Buy Now, Pay Later' services, which Affirm provides, and is expected to contribute $782 million in online spending, an 18% increase from the previous year. Affirm's stock rose 4.84% to $27.50 at the time of the report.

Portfolio Pulse from Adam Eckert

November 27, 2023 | 2:24 pm

BDRX

Biodexa Pharmaceuticals PLC-ADR (NASDAQ:BDRX) stock surged 60% after acquiring rights to tolimidone, a drug for gastric ulcers with potential in Type-1 and Type-2 diabetes treatment. Biodexa plans a Phase II study for Type-1 diabetes to confirm effectiveness. The deal includes upfront payment, milestone payments, share issuance to Melior and Bukwang, and royalties on sales. The transaction is expected to close in Q4 2023. BDRX's 52-week range is $2.26 to $579.20.

Portfolio Pulse from Henry Khederian

November 27, 2023 | 2:23 pm

PLSE

Pulse Biosciences announced it has received all necessary regulatory approvals and completed required activities to begin its planned catheter ablation feasibility study, with the first procedures scheduled for mid-December 2023.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 2:21 pm